EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Exploiting the neonatal crystallizable fragment receptor to treat kidney disease

James F Dylewski, George Haddad, Judith Blaine

Kidney International · 2024

DOI: 10.1016/j.kint.2023.09.024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney International, 2024. Verfasst von James F Dylewski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Denver Health Medical Center, Denver, CO, USA. Hauptthemen laut MEDLINE: Histocompatibility Antigens Class I, Receptors, Fc, Kidney Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The neonatal Fc receptor (FcRn) was initially discovered as the receptor that allowed passive immunity in newborns by transporting maternal IgG through the placenta and enterocytes. Since its initial discovery, FcRn has been found to exist throughout all stages of life and in many different cell types. Beyond passive immunity, FcRn is necessary for intrinsic albumin and IgG recycling and is important for antigen processing and presentation. Given its multiple important roles, FcRn has been utilized in many disease treatments including a new class of agents that were developed to inhibit FcRn for treatment of a variety of autoimmune diseases. Certain cell populations within the kidney also express high levels of this receptor. Specifically, podocytes, proximal tubule epithelial cells, and vascular endothelial cells have been found to utilize FcRn. In this review, we summarize what is known about FcRn and its function within the kidney. We also discuss how FcRn has been used for therapeutic benefit, including how newer FcRn inhibiting agents are being used to treat autoimmune diseases. Lastly, we will discuss what renal diseases may respond to FcRn inhibitors and how further work studying FcRn within the kidney may lead to therapies for kidney diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histocompatibility Antigens Class IReceptors, FcKidney DiseasesHumansAnimalsKidneyPodocytesImmunoglobulin GAutoimmune Diseases

Stichwörter der Autor:innen

AlbuminImmunoglobulin G (IgG)Podocytesneonatal Fc receptor (FcRn)

Substanzen

Fc receptor, neonatalHistocompatibility Antigens Class IReceptors, FcImmunoglobulin G

Autor:innen und Institutionen

  • Division of Nephrology, Denver Health Medical Center, Denver, CO, USA.
  • Division of Renal Disease and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Dylewski, J. F., Haddad, G., & Blaine, J. (2024). Exploiting the neonatal crystallizable fragment receptor to treat kidney disease. Kidney International. https://doi.org/10.1016/j.kint.2023.09.024

Vancouver

Dylewski JF, Haddad G, Blaine J. Exploiting the neonatal crystallizable fragment receptor to treat kidney disease. Kidney International. 2024. doi:10.1016/j.kint.2023.09.024

BibTeX
@article{Dylewski2024,
  author = {Dylewski, James F and Haddad, George and Blaine, Judith},
  title = {Exploiting the neonatal crystallizable fragment receptor to treat kidney disease},
  journal = {Kidney International},
  year = {2024},
  doi = {10.1016/j.kint.2023.09.024}
}
Kostenlos starten →